Trial Information

Summary: Follow-up Trial to Evaluate Long-Term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy

An Open-Label, Multicenter, Follow-up Trial to Evaluate Long-Term Safety and Efficacy of Ucb 34714 Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 150 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy

This trial, evaluating the long-term safety and tolerability of brivaracetam and the maintenance of efficacy over time, will give subjects suffering from partial onset seizures, who may have benefited from brivaracetam the opportunity to continue the treatment.

Inclusion Criteria:

• Male/female subjects from 16 years or older. Subjects under 18 years may only be included where legally permitted and ethically accepted.
• Inpatients or outpatients with partial onset seizures who were treated with ucb 34714 in previous trials / programs which allow access to the present trial.
• Subjects for whom the Investigator believes a reasonable benefit from the long-term administration of ucb 34714 may be expected.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: March 17, 2008 at 3:01:35 PM